← FDA DRUG APPROVALS

FDA ANDA · ANDA075383

CYTARABINE

Sponsor: HOSPIRA

APPLICATION
ANDA075383
TYPE
ANDA
ORIGINAL APPROVAL
1999-11-22
LATEST ACTION
2020-06-02
ROUTE
INTRATHECAL, INTRAVENOUS, SUBCUTANEOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

CYTARABINEPrescription
CYTARABINE 100MG/ML · INJECTABLE · INJECTION

Approval history

2020-06-02Labeling · Supplement 18 · standardAP
2019-01-15Labeling · Supplement 17 · standardAP
2018-10-03Labeling · Supplement 15 · standardAP
2001-05-14Manufacturing (CMC) · Supplement 4AP
2000-11-28Manufacturing (CMC) · Supplement 2AP
2000-10-17Manufacturing (CMC) · Supplement 1AP
1999-11-22OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →